Cover Image
市場調查報告書

CD123:免疫療法的系列的標的

CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities

出版商 La Merie Publishing 商品編碼 369010
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
CD123:免疫療法的系列的標的 CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities
出版日期: 2016年08月31日 內容資訊: 英文 83 Pages
簡介

CD123 (別名:白細胞介素-3 受體) ,是參與造血細胞的增生和分化的細胞表面蛋白質。

本報告提供CD123標靶治療調查分析,標的背景與科學性理由,前臨床概念驗證,臨床經驗,競爭情形,主要企業簡介等系統性資訊。

目錄

  • 標的背景和科學性理由
  • 抗CD123免疫療法的前臨床概念驗證
  • CD123標靶治療的臨床經驗
  • 抗CD123免疫療法的目標與治療方法的安全性的疑慮
  • 競爭情形
  • 抗CD123免疫療法簡介
  • 企業簡介
  • 參考資料
  • 附錄
目錄
Product Code: LMBR0013

This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the interleukin-3 receptor alpha subunit (IL-3Rα) is differentially and significantly overexpressed in a large proportion (up to 93 %) of patients with acute myeloid leukemia (AML) and has been identified as a marker of quiescent leukemic stem cells with very low or negligible expression in normal CD34+ progenitor cells. However, CD123 is normally expressed at low levels on some endothelial cells, monocytes, plasmocytoid dendritic cells (pDC), basophils, and myeloid progenitors. This expression profile makes CD123 an attractive surface target for novel antileukemic therapies.

Clinical experience showed that the simple blockade of interleukin-3 signalling by a naked antibody was an insufficient therapeutic strategy which opened the way for generation and devleopment of empowered anti-CD123 immunotherapeutics using emerging novel treatment modalities including:

  • Fc-engineered antibodies;
  • Immunotoxins;
  • Antibody-drug conjugates;
  • T-cell redirecting bispecific antibodies;
  • Chimeric Antigen Receptor (CAR) engineered T-cells.

This report describes the profiles of 16 different anti-CD123 immunotherapeutics based on different treatment modalities. The FDA recently acknowledged the anti-CD123 treatment approach by granting Breakthrough Therapy designation to the immunotoxin SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). SL-401 is the most advanced of 15 different anti-CD123 immunotherapeutis, seven of them are in earlier clinical develoment and further four are being prepared for clinical evaluation.

This report describes and analyzes the

  • Target Background & Scientific Rationale
  • Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
  • Clinical Experience with CD123-Targeted Treatment Modalities
  • Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD123 Immunotherapeutics
  • Company Profiles

Table of Contents

  • Target Background & Scientific Rationale
  • Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
  • Clinical Experience with CD123-Targeted Treatment Modalities
  • Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD123 Immunotherapeutics:
    • Immunotoxins
    • Naked Antibody
    • Fc-Engineered Antibodies
    • Antibody-Drug Conjugates
    • T-Cell Redirecting Bispecific Antibodies
    • Anti-CD123 CAR T-Cells
  • Company Profiles
  • References
  • ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics
Back to Top